| Customization: | Available |
|---|---|
| CAS No.: | 1208243-50-8 |
| Formula: | / |
|
Still deciding? Get samples of US$ 15/vial
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
B7-33 is a novel, synthetic compound that was first discovered and developed by a team of researchers at the Monash University in Australia. The development of B7-33 was based on the discovery of the relaxin receptor 1 (RXFP1) and the recognition of its potential as a therapeutic target for a wide range of diseases and conditions.
B7-33 is a functionally selective agonist for the relaxin receptor 1 (RXFP1), meaning that it specifically activates this receptor and its associated signaling pathways. RXFP1 is a G-protein-coupled receptor that is activated by the hormone relaxin and its related peptides. When activated, RXFP1 stimulates the production of the second messenger cyclic adenosine monophosphate (cAMP) and the subsequent activation of protein kinase A (PKA). This leads to a variety of physiological effects, such as vasodilation, decreased blood pressure, and improved kidney function. B7-33 specifically binds to and activates RXFP1. This binding leads to the activation of the cAMP-PKA pathway, which causes vasodilation and decreased blood pressure. Additionally, B7-33 has been shown to improve kidney function through increasing the blood flow to the kidney and decreasing the expression of pro-inflammatory proteins. By binding and activating RXFP1, B7-33 may mimic the effects of relaxin and related peptides, providing a potential treatment option for hypertension, kidney disease, and heart failure.
• Hypertension: B7-33 has been shown to decrease blood pressure in animal models of hypertension through its ability to activate the relaxin receptor 1 (RXFP1) and the subsequent activation of the cAMP-PKA pathway, which leads to vasodilation.
• Kidney disease: B7-33 has been shown to improve kidney function in animal models of kidney disease. Studies have shown that it increases blood flow to the kidney, decreases the expression of pro-inflammatory proteins, and improves the kidney's ability to filter waste from the blood.
• Heart failure: B7-33 has been shown to improve cardiac function in animal models of heart failure, likely through its ability to improve blood flow to the heart and decrease inflammation.
| Items | Specifications |
| Business Type | We are a manufacturer of GMP peptide and provide OEM service. The lid also can be customized |
| Filling amount | The filling amount is 2-5mg extra per bottle. |
| Purity | The purity is above 99% |
| Price | Competitive price |
| Delivery time | The delivery time is stable and short. If you pay before 12 a.m,the goods can be shipped on the same day. |
| Shipping risk | If the package was lost we will resend the goods to you,so you won't suffer a loss if you buy it. |
Zhaobo Bio acquired early mastery of development and manufacturing of peptides, the short chain amino acids linked by peptide bonds that have enabled new generations of small molecule drugs that closely mimic the body's natural pathways.
Now Zhaobo Bio possesses first-class capabilities to manufacture peptides at industrial scale and in full compliance with the strictest Good Manufacturing Practice (GMP) standards.
Upstream peptide synthesis
Zhaobo Bio production plants are endowed with state-of-the-art equipment for solvent supply, peptide synthesis, purification and isolation of active ingredients and intermediates. All equipment and containment is GMP qualified and cleaning validated. Overlapping capacities and sizes of different equipment trains facilitate a smooth scale-up for increases in demand within the product life cycle.
Downstream purification and isolation of peptides
Zhaobo Bio is committed to the systematic expansion and modernization of its purification equipment in order to ensure the efficient production of ever-increasing amounts of bulk peptide pharmaceuticals.
It uses sophisticated methods for large scale purification campaigns such as preparative high performance liquid chromatography (HPLC), ion exchange (IEX), size-exclusion chromatography (SEC), and ultra-filtration (UF/TFF). The equipment in place permits highly efficient or even continuous manufacturing of extremely pure products up to multi-kg quantities per lot.
For preparative HPLC, dynamic axial compression (DAC) stainless steel columns of up to 60 cm diameter both in batch and continuous mode are packed with the appropriate high performance silica separation phase. For low-pressure chromatography columns up to 80 cm diameter are available. Solvent delivery is ensured from eluent tank farms and containers.
The control of microbiological contamination is a prerequisite for API manufacturing. Class D (ISO 8) and C (ISO 7) clean rooms are supplied via HEPA-filtered, temperature and humidity controlled air, down-flow booths are used for minimizing microbial contamination and protecting operators. Highly active pharmaceutical ingredients are handled in integrated safety workbenches or flexible isolators reaching OEB level 4 (1-10 µg/m3).
Predefined physicochemical properties of the API can only be achieved by a carefully controlled isolation process. Besides precipitation and crystallization, lyophilization of intermediates and final API is a standard unit operation. LaixingPharma have multiple lyophilizers in different sizes (up to 300 liters) located in clean rooms.
){kind=link}